Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Pilot Trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source

Phase 1 Completed 28 enrolled Rafic Farah, MD

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether stem cells collected from a donor's blood stream will be as safe and effective as using bone marrow collected from a donor's pelvic bone.

Timeline

Start: 2015-02-11
Primary completion: 2019-09-21
Completion: 2019-09-21

Drugs

Evaluation	Drug	Modality	Dose	Route
Background	2-MERCAPTOETHANESULFONIC ACID	Small molecule	100 %	Intravenous
Background	Cyclophosphamide	Other / unclassified	14.5 mg/kg	Intravenous
Background	Cyclophosphamide	Other / unclassified	50 mg/kg	Intravenous
Background	Fludarabine	Small molecule	30 mg/m2	Intravenous
Background	G-CSF	Unknown	5 ug/kg	Subcutaneous
Background	Mycophenolate Sodium	Unknown	10 mg/kg	Oral
Background	Mycophenolate Sodium	Unknown	15 mg/kg	Oral
Background	Tacrolimus	Small molecule	0.03 mg/kg	Intravenous

Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Pilot Trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source

Summary

Timeline

Drugs

Indications